Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azelastine + montelukast
- Development stage
- Preclinical
- Lead developer
- Meda
- Modality
- Small Molecules
- Administration
- Intranasal, Oral, Ophthalmic
01
Overview
A combination therapy consisting of azelastine, a histamine H1-receptor antagonist, and montelukast, a leukotriene receptor antagonist. This combination provides enhanced efficacy in treating allergic conditions by targeting both histamine and leukotriene pathways. Clinical studies have shown that the combination provides superior protection against both early and late allergen reactions compared to either drug alone.
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on azelastine + montelukast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azelastine + montelukast.